Cosentyx is a medication used to treat various autoimmune diseases, including psoriasis and psoriatic arthritis. The active ingredient in Cosentyx is secukinumab, which works by blocking a protein that causes inflammation. While Cosentyx has been shown to be effective in treating these conditions, there are potential risks associated with its use in elderly patients.

According to Drug Patent Watch [1], the safety and effectiveness of Cosentyx in elderly patients have not been specifically studied. However, elderly patients may be more susceptible to certain side effects of the medication, such as infections and cardiovascular events. Additionally, elderly patients may have other health conditions or be taking other medications that could interact with Cosentyx.

A study published in the Journal of Clinical and Aesthetic Dermatology [2] found that elderly patients with psoriasis who were treated with Cosentyx had similar rates of adverse events as younger patients. However, the study authors noted that elderly patients may be more likely to experience serious infections and cardiovascular events, which are known risks of Cosentyx.

Another study published in the Journal of the European Academy of Dermatology and Venereology [3] found that elderly patients with psoriasis who were treated with Cosentyx had similar rates of efficacy and safety as younger patients. However, the study authors noted that elderly patients may require closer monitoring for infections and other adverse events.

In summary, while there is limited research on the use of Cosentyx in elderly patients, there are potential risks associated with its use in this population. Elderly patients may be more susceptible to infections and cardiovascular events, and may require closer monitoring for adverse events. It is important for healthcare providers to carefully weigh the potential benefits and risks of Cosentyx in elderly patients and to closely monitor these patients for any adverse events.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847154/
[3] https://pubmed.ncbi.nlm.nih.gov/32363583/